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Abstract
Background: Over the last decade, actions following some adverse drug events received major publicity. This study
investigated changes in usage patterns of medications in Australia following two examples - rofecoxib market
withdrawal (2004) and warnings about jaw necrosis following bisphosphonates (2007).
Methods: Dispensing data for COX-2 inhibitors (2000–2008) and anti-osteoporosis medications (2003–2012) were
obtained from the Australian Pharmaceutical Benefits Scheme database. For bisphosphonates, data on Australian
marketing expenditures were purchased from CegedimR.
Results: For COX-2 inhibitors, celecoxib dispensing halved after rofecoxib withdrawal, but meloxicam dispensing
increased by 60 %. When lumiracoxib was introduced (2006) there was uptake of prescribing at a faster rate than
meloxicam in 2002, its first year of use. For bisphosphonates, alendronate had highest use at the time of the warnings
(8.3 DDD/1000/day), dropping to 4.9 DDD/1000/day by 2012. In contrast, risedronate use rose 2007–2012 from 4.1 to
4.9 DDD/1000/day. There was 49 % increase in reported annual expenditure on detailing for risedronate from 2007 to
2008 (to AUD$7.3 million) and only 29 % increase for alendronate (to AUD$3.1 million).
Conclusions: The rapid uptake of prescribing of lumiracoxib and increased use of meloxicam flagged a concern,
especially after rofecoxib withdrawal due to safety issues. Bisphosphonates are useful drugs, however the dramatic rise
in expenditure on detailing, followed by a rise in utilisation of risedronate could suggest that adverse publicity triggered
a marketing response. These examples highlight the importance of tracking utilisation of medication classes in real time,
using different data as needed, to ensure that due caution is exercised (and quick intervention provided if needed) for
medications in the same class.
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Background
Post-marketing surveillance for prescribed medications
has been receiving increasing attention, from academic
researchers, prescribers, consumers and regulatory agen-
cies [1–3]. The potential adverse influence of the
pharmaceutical industry has also been identified amid
calls for a more objective mission for medicine [4]. Rare
adverse effects may not be appropriately captured during
early clinical trials, which often recruit relatively well pa-
tients with few other conditions or illnesses and in insuf-
ficient numbers to detect rare events [5]. Deleterious
effects may come to light when prescribing commences
in the more general population [1, 5]. Special vulnerabil-
ity may be due to age (both extremes of life, the elderly
and paediatric populations), concurrent illnesses and
polypharmacy. In ‘real life’, medications are used in com-
binations, not all of which can be tested in prior clinical
trials, and in people with multiple conditions, treated
and untreated [3, 5]. All too often adverse events caused
by medications are found to be important only when
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effects become reported in populations after widespread
prescribing [3]. If the use of the medication is already far
reaching, perhaps prescribed to millions of people, there
can be large absolute numbers of people affected by
‘rare’ side effects before action is taken, such as warnings
issued by regulatory bodies or medications withdrawn
from the market [1, 3].
Two recent examples of clinical adverse effects which
caused significant safety problems in large numbers of
individuals, were osteonecrosis of the jaw with bispho-
sphonates and increased risk of myocardial infarction
following rofecoxib use. These adverse events and the
effects on patient safety were the subject of mass media
current affairs television programs in Australia [6, 7].
Warnings and safety alerts for bisphosphonate-related
osteonecrosis of the jaw from regulatory agencies were
issued 2005–2007 and received extensive public media
coverage [7–10]. Alendronate was the most prescribed
bisphosphonate in Australia at this time, and by implica-
tion was associated with this adverse event [11]. Evi-
dence of rofecoxib-related increased risk of myocardial
infarction led to its market withdrawal in September
2004 [3, 12–15]. Our premise was that widespread publi-
city about these adverse effects, in the public media and
in professional publications and journals, would influence
utilisation of other medications in the same class as the
implicated drug(s), and especially influence more cautious
prescribing behaviour for medications introduced after
these adverse events in the same drug class(es).
There are, however, many influences on prescribing
behaviour, in addition to publicity and regulatory actions
or warnings about adverse events [4, 13]. Some of these
include influences of the pharmaceutical industry, the ef-
fects of peer guidelines, perceived pressure from con-
sumers or requests to prescribe, and new evidence from
published clinical trials [4, 16, 17]. Patient preferences may
also influence medicine choice, especially after media pub-
licity or warnings of potential medication-related harms.
Prescribing influences have been reviewed elsewhere
[4, 18]. Thus new medications, or medicines perceived
as somehow different from others in the same class
which have been implicated in adverse effects, may
perhaps be prescribed without due caution. At present
Australia does not have a systematic way of monitoring
use across medication classes, nor evaluating in real
time the influence of adverse events reported for one
medicine on prescribing of other medications.
The aim of this study was to investigate changes in
usage patterns of key medications in Australia following
rofecoxib market withdrawal (COX-2 inhibitor usage
2000–2008) and after the widespread warnings about
bisphosphonates (usage 2003–2012), and the resulting
publicity (both scholarly publications and public media)
about these adverse medication events.
Methods
Key dates for the two examples of adverse drug events
causing large publicity and awareness were the market
withdrawal of a COX-2 inhibitor, rofecoxib, in September
2004, and jaw necrosis from bisphosphonate use (in 2005
FDA warning added in USA; in December 2007 safety
alert issued from Therapeutic Goods Administration in
Australia), reports of which attracted extensive public
media coverage and reports in health professional literature
across Australia. Timelines for key events in the life-
cycles of COX-2 inhibitors and bisphosphonates (sub-
sidised as anti-osteoporosis medications) are shown in
Tables 1 and 2.
Dispensing data for COX-2 inhibitors (2000–2008) and
bisphosphonates (2003–2012) for Australia were obtained
from the publicly available national Pharmaceutical
Benefits Scheme (PBS) administrative database (http://www.
humanservices.gov.au/corporate/statistical-information-and-
data/pharmaceutical-benefits-schedule-statistics/). The PBS
provides subsidised pharmaceuticals to all Australian citi-
zens and residents (complete national coverage). There are
two levels of coverage, with General Beneficiaries (most of
the population) paying a higher copayment (currently 37.70
Table 1 Timeline of regulatory and public subsidy decisions for COX-2 inhibitors in Australia
1999 Jun Regulatory authority approved celecoxib for marketing in Australia
Oct Regulatory authority approved rofecoxib for marketing in Australia
2000 Jun Rofecoxib recommended to be subsidized on the PBS as a treatment for osteoarthritis only
Aug Celecoxib listed on the PBS
2001 Feb Rofecoxib listed on the PBS
Sep Regulatory authority approved meloxicam for marketing in Australia
2002 Feb Meloxicam listed on the PBS
2004 Jul Regulatory authority approved lumiracoxib for marketing in Australia
Sept Rofecoxib withdrawn from the Australian market
2006 Aug Lumiracoxib listed on the PBS
2007 Aug Lumiracoxib withdrawn from the Australian market
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Australian Dollars) than that paid by Concession Beneficiar-
ies (currently 6.10 Australian Dollars for seniors and those
receiving social security benefits). Data were downloaded for
all PBS (including the veterans (Repatriation) scheme, RPBS)
services for bisphosphonates subsidised for osteoporosis and
for concession PBS services for COX-2 inhibitors (PBS item
numbers shown in Additional files 1 and 2). PBS item num-
bers for bisphosphonates are indication-specific and those
used in this study were only for osteoporosis (not for Paget’s
Disease or other indications). Concession PBS services were
chosen for COX-2 inhibitors as at this time dispensing for
items below copayment was not captured and some of the
COX-2 inhibitors fell below General copayment for some of
that time period. The total number of services for each indi-
vidual item number (one month supply; number of tablets/
capsules specified by the recorded item number (Additional
files 1 and 2)) was obtained for each relevant calendar year.
Population numbers for Australia were obtained from the
Australian Bureau of Statistics, and for the Concession
population (seniors and social security beneficiaries) by re-
quest from Centrelink, a national government agency. Util-
isation data were calculated as World Health Organisation
(WHO) Anatomic Therapeutic Chemical (ATC) Defined
Daily Doses (DDD) (2013) per 1000 head of population
per day (DDD/1000/day = ((number of services * mg in
each service)/DDD)/(population/1000)/365). Marketing
expenditures for anti-osteoporosis medications (2003–
2011) for Australia were purchased from CegedimR
(www.cegedimstrategicdata.com), separated into the
marketing ‘channels’. These marketing data have been
described in more detail and used previously [19].
All data obtained were aggregated, with no identifica-
tion possible. Ethics approval was not required for these
publicly available data.
Results
Figure 1a) demonstrates the use of the COX-2 inhibitors
in the Australian concession beneficiary population
encompassing the time period when rofecoxib was with-
drawn from the market. Celecoxib and rofecoxib were
the market leaders, together accounting for over 50 % of
the utilisation of NSAIDs in the years 2002–2004 [12].
When rofecoxib was withdrawn from the market cele-
coxib dispensing initially increased and then fell mark-
edly in ensuing months. However, meloxicam, another
COX-2 inhibitor showed an increased utilisation over
the year following rofecoxib withdrawal. Lumiracoxib
was subsidized in the second half of 2006 and withdrawn
just over a year later, but reached utilisation similar to
celecoxib and meloxicam in that short time.
Figure 1b) details the dispensing patterns in the con-
cession population for each COX-2 inhibitor over the
initial year of each drug’s availability subsidised on the
PBS. Lumiracoxib was introduced and made available on
the PBS in 2006, after rofecoxib had been withdrawn.
Lumiracoxib showed a faster uptake rate than meloxi-
cam, which was first subsidised by the PBS in 2002, be-
fore rofecoxib withdrawal.
Figure 2 shows the PBS subsidised utilisation of the
bisphosphonates as anti-osteoporosis medications (data
for other subsidised indications, such as bone metasta-
ses, have not been included). Utilisation peaked in 2007
for total bisphosphonates. However, while alendronate
use decreased after 2007, utilisation of risedronate in-
creased and was still increasing at the end of the data
analysis period. Zoledronic acid was first subsidised by
the PBS in 2008 and had low but gradually increasing
usage by 2012. Marketing expenditures (Fig. 3), gath-
ered by the commercial company CegedimR, show that
expenditure in Australia on marketing, particularly de-
tailing, increased substantially after 2007 for risedro-
nate, and after an initial drop in 2008 began to increase
also for alendronate. This followed the time that
warnings about jaw osteonecrosis (and the safety alert
in December 2007) were published by the Australian
regulatory authority.
Table 2 Timeline of relevant activities potentially influencing utilisation of bisphosphonates in Australia (for further detail, see
Peeters et al. [10])
2001 PBS Alendronate, risendronate, etidronate available for post-menopausal women with established osteoporosis
with minimal trauma fracture
2004 ADRAC Reports of eye-problems related to bisphosphonates
2006 ADRAC Reports of osteonecrosis of the jaw related to bisphosphonates
2007 PBS Bisphosphonates, also includes women > 70years with BMD T score < −3.0
ADRAC Reports of renal impairment related to bisphosphonates, particularly zolendronic acid. Further reports of
osteonecrosis of the jaw related to bisphosphonates
Media ABC television - The 7.30 Report on osteonecrosis of the jaw related to alendronate
TGA Safety Alert -advice issued December 2007 about bisphosphonate drugs and osteonecrosis of the jaw
2008 PBS Zoledronic acid for patients with vertebral fracture
2009 PBS Zolendronic acid, also includes women > 70years with BMD T score < −3.0
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Discussion
When adverse events to a medication cause sufficient
concern for it to be withdrawn from the market, it might
be expected that other medications in the same class, es-
pecially those introduced after the withdrawal, would be
prescribed with more caution. Similarly, flagging con-
cern (issuing warnings) about adverse events to a class
of medications by regulatory agencies might also be ex-
pected to lead to caution in future prescribing of that
class. There should perhaps be a decrease in industry
promotion of those affected products with a preferred
focus on more promulgation of best evidence about how
best to use the medication class or alternatives.
In the example of COX-2 inhibitors, after rofecoxib was
withdrawn it has been reported that many people stopped
their medication [15]. However, from the sharp increases
in dispensing of other COX-2 inhibitors recorded in this
study (Fig. 1a), it seems that many rofecoxib users
switched to other medications in the same class (unless
these were all new users, but this is highly unlikely). Previ-
ous Australian data have shown changes in other NSAID
utilisation following rofecoxib withdrawal [12, 20]. Similar
switching after rofecoxib withdrawal has been reported in
other studies [14], including studies on Danish use [21]
and a comparison of six European countries [22]. How-
ever, evaluation of uptake of newer COX-2 inhibitors has
not specifically been investigated previously.
As demonstrated by Fig. 1b, even though the uptake of
prescribing of lumiracoxib in Australia was lower than
the uptake of celecoxib and rofecoxib when they were
first subsidised, the uptake rate was faster than that of
meloxicam when it was first subsidised in 2002. Given
that lumiracoxib was introduced after rofecoxib with-
drawal in Australia, it might have been expected that
Fig. 1 Utilisation of the COX-2 inhibitors (a) in the Australian concession beneficiary population from 2000 to 2008; and b over the initial year of
each drug’s subsidy on the Australian Pharmaceutical Benefits Scheme (date of introduction shown)
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prescribing would have proceeded with more caution. The
increased use of meloxicam after rofecoxib withdrawal,
shown in Fig. 1a, should also be of concern. Prescriber
characteristics for new medications, including COX-2 in-
hibitors, in the Netherlands have been previously de-
scribed, with a small subset of prescribers responsible for
a high volume of initiations of new treatments [23]. These
PBS data do not identify the prescriber, so it cannot be
ascertained whether a smaller sub-group of prescribers
accounted for most lumiracoxib and meloxicam prescrib-
ing in the wake of rofecoxib withdrawal. Ad hoc PBS data
including some prescriber attributes may be purchased
upon request, and this sub-group of data could be useful
for further investigating this question. Rofecoxib was with-
drawn due to safety issues and although there is still de-
bate about whether this is a class effect, the withdrawal
should have sounded a cautionary note about the wide-
spread prescribing of COX-2 inhibitors [24–27]. Lumira-
coxib itself was marketed in Australia for only 12 months
before its withdrawal (Aug 2007) due to concerns about
possible liver failure. Following lumiracoxib withdrawal,
utilisation of celecoxib and meloxicam did not signifi-
cantly decrease. This lack of response in celecoxib and
meloxicam dispensing after a second withdrawal from the
same drug class in a 2 year time period is also of concern.
In the second example used in this study, and as de-
scribed previously, following negative publicity relating
osteonecrosis of the jaw to bisphosphonate use and in
particular alendronate use, a drop in alendronate dis-
pensing was observed [10, 28]. This drop in alendronate
dispensing occurred despite expansion of Australian pub-
licly subsidised indications for bisphosphonates in 2008
(previously indicated for the treatment of established
osteoporosis in people with fracture due to minimal
trauma and then extended to the treatment of osteopor-
osis without fracture, in people aged 70 years or older
who have a bone mineral density (BMD) T-score of −3.0
or less), and coincided with the dramatic rise in expend-
iture on detailing (Fig. 3), followed by a rise in utilisation
of risedronate. This could suggest that adverse publicity
had triggered a marketing response, especially for risedro-
nate. The number of voluntary reports relating to osteo-
necrosis of the jaw (106) included oral alendronate (19)
and oral risedronate (2) as implicated bisphosphonates,
with the remainder being the IV formulations [8]. The lar-
ger numbers of reports with alendronate is probably due
to the prevalence of use of alendronate and its more ma-
ture stage in the product life cycle, with more people ex-
posed compared to risedronate. It would be a concern if
this difference in voluntary adverse reaction reports was
used to suggest any advantage of risedronate over the
alternate bisphosphonates. Use of other classes of anti-
osteoporosis medications has been investigated previously
in a longitudinal population study of ageing women in
Australia, and this did not show high use of these other
classes at this time [10]. Some classes only received PBS
subsidy late in the time period of interest (eg. 2009 teri-
paratide; 2007 strontium ranelate). Other adverse effects
of bisphosphonates (eg. atypical fractures, oesophageal
cancer) could have influenced prescribing but these did
not receive the attention and publicity that osteonecrosis
of the jaw did.
Zoledronic acid received PBS subsidy for osteoporosis in-
dications in 2008, as a once yearly parenteral formulation;
this was after the major publicity about osteonecrosis of
the jaw. There was an initial spike in marketing expend-
iture, especially for detailing, as expected for new products.
Use was substantially less than the oral bisphosphonates,
Fig. 2 PBS subsidised utilisation of the bisphosphonates as anti-osteoporosis medications from 2003 to 2012
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Fig. 3 Australian marketing expenditures (AUD$) in different channels, by year, for bisphosphonates (data purchased from CegedimR)
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however use was measured in DDD (4 mg) which may not
be optimal for zoledronic acid. We have used DDD ana-
lyses to allow international comparisons to our data. How-
ever, a sensitivity analysis indicated that even if a ‘usual
dose’ for zolendronic acid of 5 mg per year were used in
calculations this would not account for the decline in total
bisphosphonate usage (achieving 1.4 ‘usual daily doses’/
1000 population/year by 2012; total bisphosphonate ‘use’
11, rather than 10).
Media publicity about adverse effects can be useful in
raising public awareness of potential medication safety
issues, but the media have also been evaluated as not al-
ways reporting evidence-based decision making [29].
Osteonecrosis of the jaw is a serious adverse effect of
bisphosphonates, but with a very low prevalence and
only in a very specific subgroup [30, 31]. The problem
with the publicity was that rational explanation of the
risk was lost in the media coverage and that women with
a high fracture risk, but very low risk of necrosis, per-
haps ceased alendronate [30, 31].
The pharmaceutical industry is known to influence
prescribing decisions [4], and their mandate is to act in
the best interests of their shareholders. Innovation in
pharmaceuticals is required but the cost of this and the
effectiveness of current funding models (sales of existing
drugs) have been questioned [32]. The amount spent on
marketing can be immense and in some cases perhaps
inappropriate [4, 33]. In the case of bisphosphonates,
marketing expenditure was increased substantially for
risedronate after publicity about osteonecrosis. Risedro-
nate is now the market leader.
Regulatory agencies do have a role in preventing ac-
cess to medications likely to have safety issues. A recent
study identified that 26 % of drugs failing first cycle re-
view for approval in the US did so for safety reasons,
and a further 27 % failed due to safety and efficacy defi-
ciencies [34]. However, medications with rare adverse
events are not picked up by the usual clinical trials re-
quired for drug registration, and hence there is an ur-
gent need for new ways of monitoring medications after
market approval.
Concepts of risk and benefit need to be clearly defined
and made transparent for consumers [2]. No medication
is without risk, but the lessons learned from previous ex-
perience and new methods for post-market surveillance
including updating of risks and benefits from new medi-
cations which evolve from utilisation in large numbers
of ‘real life’ people need to be incorporated in a sys-
tematic and unbiased information resource [2, 4, 35].
In this paper, two different methods for tracking and
evaluating use after adverse event reports have been
used. The questions answered for the two examples
were distinctly different and not designed to be ad-
dressed in the same way by the same data. For the
bisphosphonates, expenditure on marketing could be
an important motivator to prescribe (after the publicity
about the adverse event) as all bisphosphonate prod-
ucts were still available but competing for market
share and to grow the market. For the COX-2 inhibi-
tors, one product, rofecoxib, was completely with-
drawn. Therefore the question was not how the
companies spent money to promote their products but
rather how these products, as members of the same
class, were being prescribed after that withdrawal. The
two examples show that different data may be needed
to explore and track what is happening after key ad-
verse events, to ensure that subsequent interventions
can successfully target better use of the medication in
the same classes. For COX-2 inhibitors, dispensing
data for the period after rofecoxib withdrawal were
evaluated, and dispensing during the first 12 months of
PBS subsidy were contrasted. For the bisphosphonates,
dispensing data for the relevant time period 2003–
2011 and also marketing data were evaluated to assess
any relationships to key dates. These examples use dif-
ferent techniques relevant to each specific medication
group and other techniques and datasets may be more
relevant for other drug(s).
Conclusions
Tracking of medication classes after adverse events have
been reported for one member of the class is important
and can give valuable information. This information
could be used, if collected prospectively in real time, to
indicate appropriate proactive interventions for other
members of the class (such as education, or regulatory
response like prior authorisation) to ensure best use of
these targeted medications. One example, the use of
COX-2 inhibitors after withdrawal of rofecoxib, has
shown that, in Australia, use of another COX-2 inhibitor,
meloxicam, increased and that the subsequent introduc-
tion of a new COX-2 inhibitor, lumiracoxib, led to wide-
spread use of this medicine before it too was withdrawn
because of adverse events. A more cautious approach
Australia-wide could have been advocated if these trends
had been prospectively monitored and interventions to
assist prescribing and use developed at the time. The
second example, the bisphosphonates and osteonecrosis
of the jaw, has shown that Australian marketing expen-
ditures by the pharmaceutical companies increased
markedly at the time of the adverse publicity. A real
time analysis of content, with perhaps opportunities for
unbiased information around product class would have
been of assistance for prescribers and consumers. There
are Australian datasets available to help track and
monitor medications classes which need to be used
prospectively in ‘real time’ to ensure best quality use
of medicines in the community.
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